OGN News

Key Factors

Recent Updates

Risk

Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.
Bearish signals are obviously dominant with 6 bearish versus 0 bullish signals.
Most recent analyst ratings for OGN are negative, with one analyst recommending a Sell rating, reflecting pessimistic market expectations.

Generated at22:0803/31/2026by

Aime

Newswire

02:49

Organon's VTAMA Efficacy Data Reinforces Immunology Strategy and Investment Narrative

23:49

Organon's Valuation Under Pressure Amid New VTAMA Data

03:29

Organon's VTAMA Data and Women's Health Grants Amidst Share Price Struggles

08:03

Organon Presents New Analysis of VTAMA Cream Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age

13:27

Organon Leads Ultra-Low P/E Stocks Amid Small-Cap Volatility

About OGN

Charts

SectorPharmaceutical

Established Date11/03/2020

Listing Date03/06/2021

ExchangeNew York Stock Exchange

Full-time Employees10000

Fiscal Year Ends31/12

Websitewww.organon.com

Security TypeCommon stock

Office address30 Hudson Street, Floor 33, Jersey City, New Jersey, 07302

Business

Introduction

Organon & Co., a company incorporated in Delaware on March 11, 2020. The company is a global healthcare company with a mission to deliver impactful medicines and solutions to make every day healthier. With a portfolio of more than 70 products in women's health and general medicines, including biosimilars, the company focuses on meeting health needs that have a unique, disproportionate or differential impact on women, while expanding access to essential treatments in more than 140 countries and regions.